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Abstract
Background: To evaluate whether apparent diffusion coefficient (ADC) value of gastric cancer obtained from
diffusion weighted imaging (DWI) correlates with the HER2 status.
Methods: Forty-five patients, who had been diagnosed with gastric cancer through biopsy, were enrolled in this
IRB-approved study. Each patient underwent a DWI (b values: 0 and 1,000 sec/mm2) prior to surgery (curative
gastrectomy or palliative resection). Postoperative microscopic findings, HER2 status by immunohistochemical
analysis and fluorescence in situ hybridization (FISH) were obtained. HER2 status was compared among gastric
cancers with various histopathological features using the chi square test. The ADC values of gastric cancers with
positive and negative HER2 were compared using the student t test.
Results: A weak yet significant correlation was observed between the mean ADC values and HER2 status
(r = 0.312, P = 0.037) and scores (r = 0.419, P = 0.004). The mean ADC value of HER2-positive gastric cancers
was significantly higher than those of HER2-negative tumors (1.211 vs. 0.984 mm2/s, P = 0.020). The minimal
ADC value of HER2-positive gastric cancers was significantly higher than those of HER2-negative tumors
(1.105 vs. 0.905 × 10−3 mm2/s, P = 0.036).
Conclusions: In this pilot study, we have demonstrated that the ADC values of gastric cancer correlate with the HER2
status. Future research is warranted to see if DWI can predict HER2 status and help in tailoring therapy for gastric
cancer.
Keywords: Diffusion magnetic resonance imaging, Stomach neoplasms, Receptor, erbB-2, Immunohistochemistry,
Molecular targeted therapy
Background
Gastric cancer is the second most common cause of
cancer-related death worldwide [1]. When diagnosed at
advanced stages, many gastric-cancer patients (especially
at M1 or T4b stage) lose the opportunity of surgical re-
section, and chemotherapy is the most effective treat-
ment to improve overall survival [2]. However, a meta-
analysis indicated that neoadjuvant chemotherapy, with
relative high adverse effects, doesn’t improve 3-year
disease-free survival [3]. The use of trastuzumab, a
monoclonal antibody against human epidermal growth
factor receptor 2 (HER2; also known as ERBB2), plus
chemotherapy proved to improve median overall sur-
vival in patients with advanced gastric or gastro-
oesophageal junction cancer, compared with chemother-
apy alone in ToGA trial [4]. Therefore, an accurate and
reliable assessment of HER2 status is important for
selecting patients with gastric cancer who may benefit
from trastuzumab treatment [5]. However, current
method assessing HER2 status either by using immuno-
histochemistry (IHC) or by fluorescence in situ
hybridization (FISH) in tumor specimens obtained from
surgical resection or endoscopic biopsy involves invasive
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procedures. Nowadays a biopsy is mandatory for the diag-
nosis and therefore the HER2 status can be known by
IHC. However, care should be taken in approaching HER2
testing in the routine workflow for gastric cancer. [6].
Nowadays, Magnetic resonance (MR) imaging is in-
creasingly used in diagnosis and staging of the gastric
cancers because it is noninvasive and provides morpho-
logical as well as functional information [7]. In particu-
lar, the diffusion weighted imaging (DWI), which reflects
the mobility of water molecule in vivo and can be quan-
tified by apparent diffusion coefficient (ADC) values, has
been widely investigated in various tumors [8–12]. Previ-
ous studies have demonstrated the value of DWI in de-
tection [13] and characterization [14] of gastric cancers.
MR imaging with DWI can increase the sensitivity and
accuracy in TNM staging of gastric cancer [15, 16], es-
pecially in T staging [17, 18]. In quantitative terms, the
ADC values could help to differentiate gastric cancers
from normal gastric walls [13–15], gastric malignancies
from benign diseases [19], and gastric adenocarcinoma
from lymphoma [20]. The ADC values also seemed a
useful tool to assess locally advanced gastric adenocar-
cinoma and gastro-oesophageal tumor response to neo-
adjuvant treatment [21, 22]. Additionally, the ADC value
of metastatic nodes was reported significantly lower than
that of the benign nodes [15, 23].
However, the correlation between the ADC values with
HER2 status of gastric cancers remains unknown. Gas-
tric cancers with different HER2 status have different
structures and behaviors, which may be reflected by the
ADC values [6, 24, 25]. Therefore, the purpose of this
study was to explore the correlations between the ADC
values and HER2 status of gastric cancers.
Methods
Patients
This study was approved by the ethics committee of
Nanjing Drum Tower Hospital. The written informed
consent was obtained from each patient. The inclusion
criteria for patients were: 1) patients aged ≥ 18 years; 2)
gastroscopic biopsy-confirmed histologic diagnosis of
gastric carcinoma; 3) absence of any absolute contraindi-
cations to MR imaging (cardiac pacemaker or defibrilla-
tor, nerve stimulator, insulin pump, aneurysm clip,
cochlear implant, etc.); 4) no prior local treatment or
systematic chemotherapy of the gastric cancer; and 5)
tumor thickness larger than 5 mm. Between December
2011 and March 2013, 45 consecutive patients (35 men
and 10 women, age: 34 ~ 80 years; mean age: 60 years)
were prospectively enrolled. Within 7 days of biopsy
(range: 3 to 7 days; mean: 5 days) and prior to surgery,
each patient underwent magnetic resonance imaging
(MRI) in the Department of Radiology.
MR examination
MR imaging was performed after the patients fasted for
over 8 h to empty the gastrointestinal tract. After con-
firming no contraindications (glaucoma, prostate hyper-
trophy or severe heart disease) were presented for the
patient, 20 mg of scopolamine butylbromide (1 ml:
20 mg; Chengdu NO.1 Drug Research Institute Com-
pany Limited, Chengdu, China) was injected intramus-
cularly to prevent gastrointestinal motility 10 min before
MR imaging. The patients drank 800 to 1000 mL warm
water 5 min before MR imaging to fill the gastric cavity.
The patients were also trained to breathe normally be-
fore MR examinations.
MR imaging was performed using a clinical whole
body 3.0 T scanner (Achieva 3.0 T TX; Philips Medical
Systems, Best, the Netherlands) with a phased-array 16-
channel sensitivity encoding multi-transmit abdominal
coil. All patients were scanned in the head-first supine
position. The field of view was set from the diaphrag-
matic dome to the level of the renal hilum.
MR sequences included: axial T2-weighted imaging,
axial DWI and multiphase contrast enhanced T1 high
resolution isotropic volume excitation imaging. Axial
T2W images were obtained with respiratory-triggered
turbo spin-echo sequence without fat-saturation
(repetition time ms/echo time ms, 1210 ~ 1220/70;
matrix, 256 × 198; section thickness 4 mm; gap,
1 mm; number of sections, 32 ~ 36; field of view,
36 cm; sensitivity encoding factor, 3.0; and number of
signals averaged, 1). The scan time of T2W imaging
was 1 min 36 s ~ 1 min 48 s. T1 high resolution iso-
tropic volume excitation with spectral attenuated in-
version recovery techniques (repetition time ms/echo
time ms, shortest/shortest; matrix, 256 × 198; section
thickness 4 mm; gap, 1 mm; number of sections, 32
~ 36; field of view, 36 cm; and number of signals av-
eraged, 1) were utilized before and 30, 60, 90 and
180 s after administration of 0.2 mL per kilogram of
body weight gadodiamide (Omniscan 0.5 mmol/mL;
GE Healthcare, Ireland) using an automatic power in-
jector (Medrad Spectris Solaris EP MR Injector Sys-
tem; One Medrad Drive Indianola, PA, USA). The
acquisition time of dynamic contrast enhanced MR
imaging was 3 min 15 s ~ 3 min 17 s.
The axial DWI was performed using the respiratory-
triggered single-shot spin-echo echo-planar sequence
with chemical shift-selective fat-suppression techniques
(b, 0 and 1000 sec/mm2; repetition time msec/echo time
msec, 2280 ~ 3600/40 ~ 50; matrix, 236 × 186; section
thickness, 4 mm; gap, 1 mm; field of view, 38 cm; num-
ber of sections, 32 ~ 36; number of signal averaged, 3).
The diffusion weighted gradients were applied to the
three orthogonal directions. The DWI scan time in this
pilot study was 3 min 45 sec ~ 4 min 24 sec.
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Image analysis
Diffusion weighted images were analyzed in work station
(Extended MR WorkSpace 2.6.3.4; Philips Medical Sys-
tems, Best, the Netherlands) and the ADC maps were
generated by using a mono-exponential fit. All the MR
images were carefully reviewed by two radiologists (Song
Liu, Zhu Ping Zhou) with 5 to 6 years of experience in
abdominal imaging. Both radiologists were informed
with the location of the lesion, and were blind to the
endoscopic and surgical pathological findings.
ADC map containing the largest slice of the tumor
was adopted and one oval region-of-interest (ROI) was
placed within the solid part of the lesion with consensus
of two radiologists. The area of the ROIs (range: 20.3 ~
95.2 mm2, mean: 45.7 mm2) may vary with the lesion
size. If the lesion showed a sandwich sign [14], the ROI
should avoid muscular layer. The mean and minimal
ADC values of each ROI were recorded. The mean ADC
value was defined as the arithmetic mean value of all the
pixels within the ROI. The minimal ADC value was de-
fined as the lowest value of all the pixels within the ROI.
Additionally, the mean and minimal ADC values of nor-
mal gastric walls of all patients were also obtained. The
area of ROIs for normal gastric wall (range: 21.5 ~
56.9 mm2, mean: 37.5 mm2) varied with the location and
distention status of the stomach.
Surgical pathological analysis
Forty-two patients underwent total or partial curative
gastrectomies; while 3 patients underwent palliative re-
sections. Gastric specimens were analyzed by two pa-
thologists with more than 10 years’ experience who were
blinded to the MRI findings. The location, maximum
diameter, histological type, differentiation degree (grade),
Lauren classification and TNM stage of gastric cancer
were evaluated.
A specific scoring system was introduced for the
HER2 assessment of the gastric cancers, which was re-
cently reinforced in consensus panel recommendations
[6]. In detail, when considering HER2 protein status de-
termination using IHC in gastric cancer resection, a pa-
tient was classified as score 3+ (IHC positive) if the
membrane staining was strong complete, basolateral or
lateral in >10 % of tumor cells; score 2+ (IHC equivocal)
if the membrane staining was weak-to-moderate
complete, basolateral or lateral in >10 % of tumor cells;
score 1+ (IHC negative) if the membrane staining was
faint/barely perceptible incomplete in >10 % of tumor
cells; and score 0 (IHC negative) if no staining was ob-
served or the membrane staining is in <10 % of tumor
cells. Equivocal cases at IHC (2+ score) were subjected
to fluorescence in situ hybridization (FISH) analysis. At
a cytogenetic level, FISH interpretation criteria were
based on a HER2/CEP17 ratio ≥2 as a cut off to define a
HER2 FISH+ test.
Statistical analysis
The mean and minimal ADC values of gastric cancers
were compared among various HER2 statues as well as
HER2 scores using a student t test or one-way variance
analysis (F test). Correlations between mean and min-
imal ADC values of gastric cancers with various HER2
statues and scores were analyzed using the Spearman’s
correlation test. HER2 status was compared among gas-
tric cancers with various histological types, differential
degrees, Lauren classifications and TNM stages using
chi square test. The two operators reevaluated separately
the whole DWI dataset and the interclass correlation co-
efficient (ICC) was estimated. The All statistical analyses
were performed with SPSS 13.0 software (SPSS Inc, Chi-
cago, Illinois). A P value less than 0.05 was considered
statistically significant.
Results
Each patient had one lesion identified. The tumors were
located in the cardia and fundus (15 cases), cardia and
body (4 cases), body (3 cases), body and antrum (4 cases)
and antrum (19 cases) of the stomach. There were 24
poorly, 11 poorly to moderately, 8 moderately and 2
moderately to well differentiated carcinomas,
respectively.
Among the 45 cases, HER2 antibody measured by IHC
staining was 3+ in 5 (11.1 %), 2+ in 7 (15.6 %) with, 1+
in 9 (20.0 %), and negative in 24 (53.3 %). FISH was
positive in 4 out of the 7 IHC 2+ cases. Hence, there
were total 9 (20.0 %) positive HER2 cases (Fig. 1) and 36
(80.0 %) negative HER2 cases (Fig. 2).
The mean and minimal ADC values of the gastric can-
cers with various HER2 statuses were shown in Table 1.
A weak, yet significant correlation was observed between
mean ADC values of the gastric cancers and HER2 sta-
tus (r = 0.312, P = 0.037), and between the mean of ADC
values and HER2 scores (r = 0.419, P = 0.004) (Fig. 3).
The minimal ADC values of gastric cancers correlated
with HER2 scores (r = 0.367, P = 0.013) rather than
HER2 status (r = 0.282, P = 0.060).
The mean and minimal ADC values of HER2-positive
gastric cancers were significantly higher than those of
HER2-negative tumors (1.211 vs. 0.984, 1.105 vs.
0.905 × 10−3 mm2/s, P = 0.020, 0.036, respectively). The
mean and minimal ADC values of HER2 (3+) gastric
cancers were significantly higher than those of HER2-
negative (0) tumors (1.295 ± 0.290 vs. 0.934 ± 0.215,
1.164 ± 0.349 vs. 0.861 ± 0.217 × 10−3 mm2/s, P = 0.004,
0.016, respectively).
The histopathological features of the gastric cancers
with various HER2 statuses were shown in Table 2. The
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HER2-positive rate in gastric cancers of the interstitial
type (6/11, 54.5 %) was significantly higher than that of
the diffuse type (2/30, 6.7 %) (P = 0.003).
The ICC of mean ADCs between two operators was
0.987 (95 % confidence interval: 0.982 ~ 0.990, P < 0.001)
and the ICC of minimal ADC was 0.954 (95 % confi-
dence interval: 0.929 ~ 0.969, P < 0.001), which showed
an excellent inter-reader agreement of measured ADC
values.
Discussion
The HER2 (also known as ErbB2, c-erbB2, or Her2/neu)
gene is located on chromosome 17q and encodes a
185 kDa transmembrane tyrosine kinase receptor pro-
tein with no known ligand [23]. HER2 forms both
homo- and heterodimers and leads to activation of
downstream signaling pathways to promote cell prolifer-
ation and suppress apoptosis, which may facilitate exces-
sive/uncontrolled cell growth and tumorigenesis [26].
HER2 overexpression and/or amplification was reported
in various solid tumors, such as breast, gastric, ovarian
[27, 28], colorectal [29], salivary gland [30], bladder [31],
and lung cancers [32]. The importance of HER2 as a key
marker in gastric tumorigenesis has very recently come
to light. Because of differences in the examination
method and objective criteria, the frequency of HER2-
positive gastric cancer varies considerably between stud-
ies, ranging from 6.0 % to 29.5 % in earlier studies [33].
A number of studies have shown that HER2 overexpres-
sion and amplification are related to the Lauren histo-
logical classification, with higher HER2 positivity rate
found in the intestinal phenotype than in diffuse and
mixed types [34], which was consistent with our finding.
Recent study shows that HER2 alteration or overexpres-
sion was more frequently observed in the well or moder-
ately differentiated type than poorly-differentiated
gastric cancers [35–37]. Her2 expression/amplification
was also associated with earlier tumor stages and ab-
sence of lymph node metastases [38]. Other factors cor-
relating with HER2 overexpression include age, gender,
tumor location, size, histological type, Bormann type, et
al [39]. However, the prognostic value of HER2 amplifi-
cation/over-expression in patients with gastric cancer re-
mains controversial [24, 40].
We found that the ADC values of gastric cancers were
higher in patients with positive HER2 expression than
negative neoplasms. Our previous studies have con-
firmed the correlations between ADC values of gastric
cancers with the Lauren classifications, differential de-
grees and TNM stages [41]. We found that ADC values
Fig. 1 A 69-year-old man with gastric cancer, at stage IIIA (T3N2M0). Axial diffusion weighted image (b = 1000 sec/mm2) (a) shows the lesion with
remarkably high signal intensity in antrum (arrow) of stomach with a maximum diameter of 5.0 cm. An oval region-of-interest (ROI) with an area
of 43.7 mm2 is placed within the solid part of the lesion in corresponding apparent diffusion coefficient (ADC) map (b), which shows restricted
mean and minimal ADC values as 1.148 and 0.970 × 10−3 mm2/s respectively. Photomicrograph (Hematoxylin & Eosin staining, ×200) (c) proves
moderately differentiated adenocarcinoma with a Lauren classification of intestinal type. HER2 immunohistochemical assay (d) shows complete
and intense circumferential membrane staining in >10 % of tumor cells (score 3+)
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of gastric cancer with intestinal type, well differentiation
and early stages were higher than those with diffuse
type, poor differentiation and advanced stages. Tubular
or gland structures are commonly observed in the intes-
tinal type, which may lead to relatively large spaces for
water molecular Brownian motion. Low differentiation
degree and high level of cellular atypia are common fea-
tures of diffuse type, which may cause narrower and
more distorted intercellular spaces. We also found that
the ADC values of the gastric cancer correlated inversely
with T stage [41]. We hypothesized that as the T stage
improves the amount and density of tumor cells increase
while their arrangement is disordered. Large cell
column, increased nucleus/cytoplasm ratio and irregular
cell shape cause narrower and distorted intercellular
spaces, and as a result, a decreased ADC value. Since
HER2 expression is higher in gastric cancers with intes-
tinal type, well differentiation and early stages, and con-
sequently, a higher ADC values were observed in gastric
cancers with positive HER2 expression.
Similar correlation between ADC values and HER2
status can also been observed in breast cancers. Ji
Hyun Youk et al. [42] reported that the mean ADC
value of triple-negative invasive breast cancer was
significantly higher than that of ER+ (P = 0.002) and
HER2+. However, Melania Costantinithe et al. [43]
found that average ADC values measured in triple-
negative breast cancer were slightly lower than those
observed in HER2-overexpressing subgroups with no
statistical significance. Bo Bae Choi et al. [44] found
significant low ADC values in invasive ductal carcin-
oma with HER2-negative expression (P <0.05). And
Laura Martincich et al. [45] found that the subtype
of pure HER2-enriched tumors had the highest me-
dian ADC value (1.190 × 10−3 mm2/s), compared
with the other immunohistochemically defined in-
trinsic tumor subtypes.
As the overexpression and/or amplification of HER2
enables the constitutive activation of growth signaling
Fig. 2 A 58-year-old man with gastric cancer, at stage III B (T3N3M0). Axial diffusion weighted image (b = 1000 sec/mm2) (a) shows a hyperintense lesion
in antrum (arrow) of stomach with a maximum diameter of 6.0 cm. Note the bright lymph node metastasis (curved arrow). An oval region-of-interest (ROI)
with an area of 22.0 mm2 is placed within the solid part of the lesion in corresponding apparent diffusion coefficient (ADC) map (b), which shows restricted
mean and minimal ADC values as 0.918 and 0.867 × 10−3 mm2/s. Photomicrograph (Hematoxylin & Eosin staining, ×200) (c) reveals signet ring cell
carcinoma with a Lauren classification of diffuse type. HER2 immunohistochemical assay (d) shows no membrane staining is observed (score 0)
Table 1 Mean and min ADC values (×10−3 mm2/s) of gastric
cancers with different HER2 status
HER2 status n mean ADC P value min ADC P value
Score (0) 24 0.934 ± 0.215 0.022* 0.861 ± 0.217 0.060*
Score (1+) 9 1.068 ± 0.312 0.970 ± 0.273
Score (2+) 7 1.116 ± 0.208 1.041 ± 0.217
Score (3+) 5 1.295 ± 0.291 0.004§ 1.164 ± 0.349 0.016§
Negative (-) 36 0.984 ± 0.242 0.020‡ 0.905 ± 0.230 0.036‡
Positive (+) 9 1.211 ± 0.286 1.105 ± 0.314
*one-way analysis of variance among score 0-3; §LSD method between score 0
and 3+; ‡student t test between negative (-) and positive (+) groups
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pathways which are heavily involved in the carcinoge-
netic process, direct targeting of HER2 and inhibition of
the HER2-activated signal transduction is likely to pro-
vide therapeutic possibilities for HER2-positive patients
[46]. A recent meta-analysis has confirmed that addition
of trastuzumab (anti-HER2 antibody) to chemotherapy
for gastric and gastroesophageal cancer significantly im-
proved outcome of overall survival and progression-free
survival endpoints, while other monoclonal antibodies
led to no improvement in results [25]. Trastuzumab in
combination with chemotherapy is currently routine
practice for patients with HER2-positive advanced eso-
phagogastric adenocarcinoma [47].
DWI has been widely applied to predict and monitor
treatment response in different types of neoplasm [48–
50]. Francesco DC et al. [21] reported that the pretreat-
ment ADC values of gastro-oesophageal cancer in re-
sponders were significantly lower and increased
significantly after neoadjuvant treatment of radio-
chemotherapy, since high pre-treatment ADC values are
related to the presence of necrotic components, poor
perfusion, and hypoxic environment, leading to a re-
duced sensitivity to neoadjuvant treatment. Therefore,
DWI shows the potential to identify pre-treatment fea-
tures affecting the gastric cancer response to neoadju-
vant treatment. However, Francesco G et al. [22]
Fig. 3 Box plots of mean (a) and minimal (b) apparent diffusion coefficient (ADC) values of gastric cancers with different HER2 scores
Table 2 Histopathological features in gastric cancers with different HER2 status
HER2(+) HER2(-) P value
N 9 36
Gender (M/F) 6/3 23/13 0.876
Age (mean ± SD) 60.3 ± 10.7 61.6 ± 11.2 0.755
Diameter (mean ± SD) 5.11 ± 2.89 5.11 ± 2.21 1.000
Diameter (<3 cm/>3 cm) 2/7 10/27 0.768
Diameter (<4 cm/>4 cm) 5/4 14/22 0.365
T stage (1/2/3/4) 0/2/6/1 6/5/20/5 0.569
N stage (0/1-3) 2/7 9/27 0.862
M stage (0/1) 8/1 35/1 0.278
TNM stage (I/II/III/IV) 1/2/5/1 6/11/18/1 0.686
Lauren classification (intestinal/ mixed/diffuse type) 6/1/2 5/3/28 0.003*
Pathologic type(adenocarcinoma /signet ring cell cancer) 7/2 30/6 0.697
Differentiation degree of adenocarcinomas (poor/poor-mod/mod/mod-well)§ 4/2/1/0 12/9/7/2 0.784
Overall differentiation degree (poor/poor-mod/mod/mod-well)‡ 6/2/1/0 18/9/7/2 0.758
Location (cardia&fundus/cardia&body/ body/body&antrum/antrum) 2/2/0/2/3 13/2/3/2/16 0.209
§poor, poorly; poor-mod, poorly to moderately; mod, moderately; mod-well, moderately to well; ‡ signet ring cell cancer was treated as poorly differentiated;
* P < 0.05
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reported that no significant differences could be found
for prechemotherapy ADC values of gastric adenocarcin-
oma between responders and nonresponders. Anyway,
no study on the performance of ADC values in trastuzu-
mab plus chemotherapy for gastric cancers has been re-
ported, which needs further studies.
There were some limitations in our study. Firstly, the
samples size was relatively small and the correlation be-
tween ADC values and HER2 status was weak. Since the
application of DWI in gastric cancer is just beginning, it
was relatively large in this field and is essentially enough
for a pilot study. We are accumulating more cases to
confirm our findings in this study. Secondly, the patho-
logic foundation and mechanism of higher ADC values
in gastric cancers with positive HER2 expression were
only speculative. Thirdly, other biomarkers such as epi-
dermal growth factor receptor 1 and 3, vascular endo-
thelial growth factor, Ki67 were not analyzed in this
study. Fourthly, b = 0 and 1000 sec/mm2 cannot elimin-
ate the influence of perfusion, which could be resolved
by using multiple b values with bi-exponential model.
Further studies are required to address those limitations.
Conclusions
ADC values from DWI reflected different HER2 status
of gastric cancers. Although the molecular biomarkers of
gastric cancers cannot be determined solely by ADC
values, DWI procedure is noninvasive, costs short acqui-
sition and post-processing time, and requires no contrast
agent administration. Preoperative DWI, which provides
real quantitative functional parameter, is promising in
tailoring therapy for gastric cancers.
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